本页面由Tiger Fintech (Singapore) Pte. Ltd.提供服务

BridgeBio Pharma, Inc.

31.37
-2.7000-7.92%
盘后31.03-0.3400-1.08%17:35 EDT
成交量:401.52万
成交额:1.28亿
市值:59.66亿
市盈率:-10.90
高:33.89
开:33.37
低:30.86
收:34.07
数据加载中...
2024/02/22

重要事件披露

Form 8-K - Current report
2024/02/16

超过5%披露

Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
2024/02/16

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2024/02/14

超过5%披露

Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
2024/01/18

重要事件披露

Form 8-K - Current report
2024/01/17

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2024/01/09

重要事件披露

Form 8-K - Current report
2024/01/06

员工持股计划

Form S-8 - Securities to be offered to employees in employee benefit plans
2023/12/27

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2023/12/19

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2023/12/15

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2023/12/01

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2023/11/22

超过5%披露

Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]
2023/11/17

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2023/11/17

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2023/11/15

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2023/11/02

重要事件披露

Form 8-K - Current report
2023/11/02

季度报告

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
2023/09/25

重要事件披露

Form 8-K - Current report
2023/09/05

关联方拟减持公告

Form 144 - Report of proposed sale of securities